Contraindication

A contraindication is a documented reason not to give a treatment to a particular person. The nearest formal UK-relevant definition comes from medicines regulation: a contraindication is a situation in which a medicinal product must not be given for safety reasons, while lesser concerns belong under special warnings and precautions.^{[7]A contraindication is a documented reason not to give a treatment to a particular person; the nearest formal definition in UK-relevant regulation is the medicines one, which reserves the term for 'situations where the medicinal product must not be given for safety reasons' and puts everything softer into a separate section headed 'special warnings and precautions for use'.Directly tested by the source[7] European Commission. A Guideline on Summary of Product Characteristics (SmPC), Revision 2, September 2009. Notice to Applicants, Volume 2C (29 pages).Tier 1}

In everyday aesthetics teaching, absolute contraindication usually means that the treatment does not proceed, while relative contraindication means that risk must be weighed and the treatment may be modified or deferred. The distinction is useful, but it is not codified for non-surgical cosmetic procedures. The JCCP/CPSA Code does not use the word “contraindication”; in Ofqual’s 303,554-unit extract, “absolute contraindication” appeared once in a perinatal exercise unit and “relative contraindication” did not appear.^{[13, 15]}

A lack of data is not automatically a contraindication. The medicines guideline states that lack of data alone should place an issue under warnings and precautions rather than create a bar to use. Cosmetic practice borrows that discipline; no equivalent rule binds the whole sector.^{[7]Medicines regulation is explicit that uncertainty is not itself a reason to bar a product: the SmPC guideline states 'Lack of data alone should not lead to a contraindication', and directs untested populations to the warnings-and-precautions section instead. Nothing equivalent binds cosmetic procedures — the discipline is borrowed, not imposed.Directly tested by the source[7] European Commission. A Guideline on Summary of Product Characteristics (SmPC), Revision 2, September 2009. Notice to Applicants, Volume 2C (29 pages).Tier 1}

Five sources commonly generate a contraindication or caution: the manufacturer’s instructions, insurer policy wording, an awarding-body specification, a professional standard and clinical evidence. They do not necessarily agree. The CPSA skin-rejuvenation standard, for example, defers peel depth, preparation and allergy testing to manufacturer guidance; awarding bodies mostly do not name individual contraindications; the JCCP/CPSA Code does not use the term; and insurers set scope partly by profession and training route.^{[13, 14, 15, 16]Five different authorities generate the contraindications a UK practitioner is taught — manufacturer instructions, insurer underwriting, awarding body specifications, professional body standards and clinical evidence — and they demonstrably disagree: the CPSA skin rejuvenation standard defers depth, prep and allergy testing to 'manufacturer guidelines', the awarding bodies mostly do not name contraindications at all, the JCCP/CPSA Code never uses the word, and insurers set scope by profession rather than by risk.Directly tested by the source[13] Joint Council for Cosmetic Practitioners and Cosmetic Practice Standards Authority. JCCP and CPSA Code of Practice and Guidance for Practitioners Who Provide Cosmetic Interventions, Third Edition. March 2023. 33 pages.Tier 4[14] Cosmetic Practice Standards Authority. Skin Rejuvenation Standards (chemical peels and micro-needling). CPSA; document dated February 2018, 18 pages.Tier 4[15] Ofqual, Register of Regulated Qualifications — Units full extract (Units.csv, 303,554 unit records). Downloaded and analysed 2 August 2026; counts independently re-run on the same file 2 August 2026. Ofqual regulates qualifications in England.Tier 3[16] Hamilton Fraser. Medical malpractice insurance — cosmetic insurance for aesthetic practitioners. Company web page, accessed 2 August 2026.Tier 4}

The JCCP separately names only five benchmarked modalities—hair restoration surgery, injectable toxins, dermal fillers, lasers and light, and skin rejuvenation through microneedling or chemical peels—and says it has no benchmark proficiency standard for treatments it calls adjunctive or orphan. That is a self-published position from a voluntary register, not law.^[17]

For a medical device, the manufacturer’s instructions for use have a specific legal role. The Medical Devices Regulations 2002 define intended purpose by the manufacturer’s labelling, instructions and promotional material. A restriction in the instructions is therefore more than optional advice about technique.^{[9]For a medical device such as a microneedling pen, laser, IPL or radiofrequency platform, the manufacturer's instructions for use are not advice but the legal definition of what the device is for: UK MDR 2002 defines 'intended purpose' as the use intended 'according to the data supplied by the manufacturer on the labelling, the instructions for use and/or the promotional materials'.Directly tested by the source[9] The Medical Devices Regulations 2002 (S.I. 2002/618), regulation 2 (interpretation), as amended and applying in Great Britain; MHRA is the competent authority.Tier 1}

For a professional peel or skincare cosmetic in Great Britain, cosmetic law requires the label to carry particular precautions, including precautions for professional use. That is a product-level duty on the Responsible Person; it does not create a universal client-selection list.^{[8]For a professional peel or skincare product, which is a cosmetic product rather than a device or medicine, GB law requires the packaging to carry 'particular precautions to be observed in use... and any special precautionary information on cosmetic products for professional use' — a product-level duty on the responsible person that says nothing about which clients a practitioner should decline.Directly tested by the source[8] Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products, Article 19 (Labelling), as assimilated law applying in Great Britain.Tier 1}

Jurisdiction also matters:

• England: no licensing scheme is in force. The green/amber/red placements came from the 2023 consultation; the 2025 response said further work was required before procedures could be assigned.^{[3, 4]England has no licensing scheme in force; the green/amber/red tiers that place superficial peels and microneedling in green and medium-depth peels in amber come from the 2023 consultation proposal only, and the August 2025 government response stated that 'further work is required to determine where specific procedures will sit in the proposed tiering system'.Directly tested by the source[3] Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation document. London: DHSC; consultation opened 2 September 2023, closed 28 October 2023.Tier 1[4] Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. London: DHSC; published 7 August 2025.Tier 1}
• Scotland: the 2026 Act specifies microneedling at any depth with radiofrequency, microneedling at 1.5 mm or deeper otherwise, and peels penetrating beyond the epidermis. Only definitions and regulation-making powers had commenced on 22 July 2026; the substantive offences in sections 2(1) and 3 were not yet in force.^{[5]Scotland has legislated real thresholds that turn on treatment depth: the Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 specifies microneedling at any depth with radiofrequency or at 1.5mm or more otherwise, and chemical peels penetrating deeper than the epidermis — but the substantive offences in sections 2(1) and 3 are not yet in force, only the definitions and regulation-making powers commenced on 22 July 2026.Directly tested by the source[5] Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 (2026 asp 13), schedule 1; and the Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 (Commencement No. 1 and Saving Provision) Regulations 2026 (S.S.I. 2026/206).Tier 1}
• Wales: the statutory special-procedures scheme covers acupuncture, body piercing, electrolysis and tattooing. It does not cover chemical peels, microneedling, laser or IPL.^{[6]Wales licenses only four special procedures — acupuncture, body piercing, electrolysis and tattooing — under section 57 of the Public Health (Wales) Act 2017, in force since 29 November 2024; chemical peels, microneedling, laser and IPL fall entirely outside that scheme.Directly tested by the source[6] Public Health (Wales) Act 2017 (anaw 2), Part 4, section 57 ('Meaning of special procedure').Tier 1}

An insurer may be more restrictive than law or a voluntary professional standard. One leading UK insurer requires relevant face-to-face theoretical and practical training and does not insure non-medics such as beauty therapists or dental nurses for injectables. Its public page is marketing information rather than policy wording, so the actual contract remains the operative document.^{[16]An insurer can be more restrictive than either the law or the professional standards, and often is: a leading UK aesthetics insurer conditions cover on holding 'the relevant theoretical and practical face to face training and qualifications' and states plainly that it does 'not insure non-medics such as beauty therapists or dental nurses for injectable treatments'.Directly tested by the source[16] Hamilton Fraser. Medical malpractice insurance — cosmetic insurance for aesthetic practitioners. Company web page, accessed 2 August 2026.Tier 4}

A treatment does not proceed where the product or device instructions prohibit it, where the practitioner lacks the training or insurance required for it, or where the proposed act falls outside professional scope. The treatment-specific entry and the instructions for the exact product or device supply the detailed list.

The CPSA standard frames pregnancy, breastfeeding, diabetes, smoking, steroid use, immunosuppression and photosensitising medicines as cautions for peels or microneedling. It states no absolute contraindication and supplies no evidence citations for those cautions. That does not remove them; it identifies their status and the authority from which they came.^{[14]The benchmark UK standard for peels and microneedling frames pregnancy, breastfeeding, diabetes, smoking, steroid use, immunosuppression and photosensitising medication as 'patient-related cautions' — 'not recommended', 'caution is advised' — and states no absolute contraindication anywhere, without citing evidence for any of them.Directly tested by the source[14] Cosmetic Practice Standards Authority. Skin Rejuvenation Standards (chemical peels and micro-needling). CPSA; document dated February 2018, 18 pages.Tier 4}

Where a caution is being considered rather than an absolute bar, material risk is person-specific. In Montgomery v Lanarkshire Health Board, the Supreme Court required disclosure of material risks and reasonable alternatives, judged by what a reasonable person in that individual’s position would consider significant. The judgment concerned a doctor. It said its reasoning was relevant, with necessary changes, to other healthcare providers, but it did not decide the standard owed by a non-registered aesthetic practitioner.^{[1]UK consent law was settled by the Supreme Court in Montgomery v Lanarkshire Health Board [2015] UKSC 11: at paragraph 87, 'The doctor is therefore under a duty to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment, and of any reasonable alternative or variant treatments', materiality being whether 'a reasonable person in the patient's position would be likely to attach significance to the risk'. The judgment says 'doctor'; how far it reaches beyond registered clinicians is a separate question (see ci-montgomery-reach).Directly tested by the source[1] Montgomery v Lanarkshire Health Board (Scotland) [2015] UKSC 11, judgment of the Supreme Court of the United Kingdom, 11 March 2015 (Lords Neuberger, Kerr, Clarke, Wilson, Reed, Hodge and Lady Hale).Tier 1[1]Montgomery concerned an obstetrician, and the Supreme Court said the judgment 'is also relevant, mutatis mutandis, to other healthcare providers' — but it did not decide the standard of care owed by a non-registered cosmetic practitioner, so the extension to beauty and aesthetic therapists is a reasonable reading rather than a settled ruling.Directly tested by the source[1] Montgomery v Lanarkshire Health Board (Scotland) [2015] UKSC 11, judgment of the Supreme Court of the United Kingdom, 11 March 2015 (Lords Neuberger, Kerr, Clarke, Wilson, Reed, Hodge and Lady Hale).Tier 1}

Risk materiality cannot be reduced to a percentage. A rare visible facial injury may matter greatly to one person, while a common transient effect may matter less; the nature and consequence of the outcome are part of the assessment.^[1]

Source-based client selection

Isotretinoin and the six-month rule

The selection question is not which generic list is longest. It is which authority governs the exact product, device, treatment, jurisdiction and practitioner.

A defensible record identifies whether an item came from the manufacturer’s instructions, the insurer’s policy wording, a professional standard, an awarding-body requirement or clinical evidence. Where those sources conflict, the most restrictive contractual or product requirement may still govern even where the clinical literature is less restrictive.

The JCCP/CPSA Code says relevant discussions must be recorded contemporaneously. It also requires a refusal to involve the client’s GP to be recorded with its effect on the balance of risk and benefit. Device or medicine traceability is expressed more softly: records should allow all clients exposed to a particular device or medicine to be identified after a safety concern.^{[13]Where a practitioner proceeds despite a caution, the professional standard requires the reasoning to be written down at the time: discussions 'must be recorded contemporaneously in your clinical notes' (paragraph 38), and a client's refusal to involve their GP 'must' be recorded together with how it affects the balance of risk and benefit (paragraph 48). Batch and device traceability is put more weakly — paragraph 60 says you 'should' organise records so that everyone treated with a particular device or medicine can be identified if a safety concern later emerges.Directly tested by the source[13] Joint Council for Cosmetic Practitioners and Cosmetic Practice Standards Authority. JCCP and CPSA Code of Practice and Guidance for Practitioners Who Provide Cosmetic Interventions, Third Edition. March 2023. 33 pages.Tier 4}

A consent form is not a substitute for the discussion. Montgomery states that the duty is not fulfilled by overwhelming a person with technical information or routinely demanding a signature.^{[1, 2]A signed consent form does not discharge the duty: Montgomery states at paragraph 90 that the duty 'is not therefore fulfilled by bombarding the patient with technical information which she cannot reasonably be expected to grasp, let alone by routinely demanding her signature on a consent form', and the GMC frames consent as 'an ongoing process focused on meaningful dialogue' (GMC wording could not be re-verified at source — gmc-uk.org returns HTTP 403 to automated requests — so the load-bearing half of this claim is the Montgomery quotation, which was read in the judgment PDF).Directly tested by the source[1] Montgomery v Lanarkshire Health Board (Scotland) [2015] UKSC 11, judgment of the Supreme Court of the United Kingdom, 11 March 2015 (Lords Neuberger, Kerr, Clarke, Wilson, Reed, Hodge and Lady Hale).Tier 1[2] General Medical Council. Decision making and consent. Manchester: GMC; published 30 September 2020, came into effect 9 November 2020.Tier 1}

Proceeding through a true contraindication

Treating a precaution as an absolute bar

Documentation failures

Referral is indicated where the presentation may be a medical diagnosis, a medicine decision is required, a systemic condition or prescription could materially alter risk, or a complication exceeds the practitioner’s competence and available support.

Questions about starting, stopping or changing isotretinoin belong to the prescriber. The evidence above informs timing around specific procedures; it does not authorise a non-prescriber to alter the medicine.

Where uncertainty remains but the product instructions prohibit treatment, the product restriction governs unless the manufacturer supplies a documented position. Where the restriction comes only from custom and the potential consequence is clinically important, medical or appropriately qualified specialist assessment is preferable to converting uncertainty into reassurance.

A contraindication has no biological mechanism of its own. It is a decision category linking a person’s characteristics, the intended intervention and a potential harm. An absolute contraindication closes that pathway; a precaution changes the risk-benefit assessment, the timing or the need for another clinician’s input.

The distinction is useful because it prevents three different things being collapsed into one list: biological risk, a product’s intended-purpose boundary and a practitioner’s scope or insurance boundary.^{[7, 9, 13, 14, 15, 16]}

“Absolute and relative contraindications are a UK professional standard.”

“Every treatment must wait six months after Roaccutane.”

“Chemical peels and microneedling are green tier in England.”

“A signed consent form protects the practitioner.”

• Whether Montgomery applies in full to non-registered cosmetic practitioners has not been decided on those facts; until it is, person-specific disclosure and contemporaneous recording remain the safer professional standard.
• Whether medium-depth and deep peels are riskier during or shortly after isotretinoin remains unknown; the studies that challenged the blanket delay did not resolve these procedures, so their instructions and specialist advice still govern.
• The pooled adverse-event estimates for isotretinoin with laser are extremely imprecise; they cannot exclude uncommon scarring or pigmentary harm, so a non-significant result must not be used as reassurance.^[12]
• No clinical evidence was located for the pregnancy caution on superficial peels or microneedling; the caution remains in professional standards, so it should be described as precautionary rather than as a quantified risk.^[14]
• England’s final tiers and the commencement details for Scotland’s substantive offences remain unsettled; jurisdiction must therefore be checked at the time scope is assessed.^{[3, 4, 5]}
• Public insurer pages do not reveal binding exclusions; the practitioner’s own policy wording remains necessary before cover can be assumed.^[16]

Is a relative contraindication permission to treat?

Does the manufacturer’s list override published evidence?

Is the six-month isotretinoin rule obsolete?

Are England’s licensing tiers already law?

What should happen when two sources disagree?

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

1. Montgomery v Lanarkshire Health Board (Scotland) [2015] UKSC 11, judgment of the Supreme Court of the United Kingdom, 11 March 2015 (Lords Neuberger, Kerr, Clarke, Wilson, Reed, Hodge and Lady Hale).Tier 1Supports: Governing UK law on consent to treatment. Para 87 verbatim: 'The doctor is therefore under a duty to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment, and of any reasonable alternative or variant treatments. The test of materiality is whether, in the circumstances of the particular case, a reasonable person in the patient's position would be likely to attach significance to the risk, or the doctor is or should reasonably be aware that the particular patient would be likely to attach significance to it.' Para 89: 'the assessment of whether a risk is material cannot be reduced to percentages.' Para 90: the doctor's duty 'is not therefore fulfilled by bombarding the patient with technical information which she cannot reasonably be expected to grasp, let alone by routinely demanding her signature on a consent form.' SCOPE LIMIT: the case concerned an obstetrician and a shoulder-dystocia risk in childbirth, and the ratio is expressed in terms of doctors. Para 75 states that 'a wider range of healthcare professionals now provide treatment and advice of one kind or another to members of the public... (with the consequence that, although this judgment is concerned particularly with doctors, it is also relevant, mutatis mutandis, to other healthcare providers).' The Court did not rule on non-registered cosmetic practitioners, and the standard of care for a non-clinician performing a beauty treatment has not been settled on these facts. Full 38-page judgment retrieved and read; BAILII blocked automated access (bot-check page).
2. General Medical Council. Decision making and consent. Manchester: GMC; published 30 September 2020, came into effect 9 November 2020.Tier 1Supports: The GMC's seven principles, quoted verbatim from the published guidance: (1) 'All patients have the right to be involved in decisions about their treatment and care and be supported to make informed decisions if they are able.' (2) 'Decision making is an ongoing process focused on meaningful dialogue: the exchange of relevant information specific to the individual patient.' (3) 'All patients have the right to be listened to, and to be given the information they need to make a decision and the time and support they need to understand it.' (4) 'Doctors must try to find out what matters to patients so they can share relevant information about the benefits and harms of proposed options and reasonable alternatives, including the option to take no action.' (5) presumption of capacity; (6) overall benefit where capacity is lacking; (7) support where the right to consent is affected by law. The guidance is structured with paragraphs 50-55 on 'Recording decisions' (patients' medical records, visual and audio recordings, consent forms). SCOPE LIMIT: this guidance binds registered doctors only. It has no direct disciplinary force over beauty therapists, aestheticians or other non-registered practitioners, even though CPSA standards written for those practitioners cross-refer to it. ACCESS NOTE: gmc-uk.org returned HTTP 403 to automated requests (Cloudflare); text verified from Internet Archive snapshots dated 1 March 2024 and 12 September 2024. Paragraph-level text of paras 50-55 was not retrievable.
3. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation document. London: DHSC; consultation opened 2 September 2023, closed 28 October 2023.Tier 1Supports: The only document that has ever set out the proposed English green/amber/red tiers with named procedures. Tier definitions verbatim: green — 'procedures with the lowest risk of complications. All practitioners are eligible to perform licensed procedures where they meet agreed standards'; amber — 'procedures with medium risk of complications. Non-healthcare professionals must be licensed and have relevant oversight by a named regulated healthcare professional'; red — 'procedures with the highest risk of complications', to be brought into CQC regulation. Green as proposed included microneedling, mesotherapy, IPL, LED, superficial chemical peels, no-needle fillers, micropigmentation/microblading, non-ablative laser hair removal and photorejuvenation. Amber included botulinum toxin, semi-permanent dermal fillers (face only), PRP, medium-depth chemical peels, HIFU, radiofrequency, plasma ablation and non-ablative lasers other than photorejuvenation/hair removal. Red included thread lifts, hair restoration surgery, body augmentation, dermal micro-coring, deep chemical peels and extensive ablative CO2 resurfacing. SCOPE LIMIT: this is a CONSULTATION PROPOSAL, not law. No licensing scheme is in force in England, and nothing in this document has legal effect. It is nevertheless the document most often quoted in training as if it were settled.
4. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. London: DHSC; published 7 August 2025.Tier 1Supports: The government response explicitly declines to place individual procedures in tiers. Verbatim: 'Based on the views expressed through the responses to this consultation, we are not proposing at this stage to remove any of the procedures currently included within the scope of the licensing scheme or associated regulation, nor are we proposing to add any further procedures'; and 'further work is required to determine where specific procedures will sit in the proposed tiering system.' On sequencing, verbatim: 'the government will therefore prioritise initial work in this space on the introduction of legislation which will ensure that those procedures deemed to pose the highest level of risk (including procedures aimed at augmenting the breast, buttocks and genitals with dermal fillers) can only be performed by suitably qualified regulated healthcare professionals working for CQC-registered providers. The proposed changes will be detailed in a public consultation, to be launched early next year.' On age: 'The consultation has strengthened our intention to mandate age restrictions for those undergoing non-surgical cosmetic procedures.' The response records 11,848 responses to the 2023 consultation (that figure is published here, in the response, not in the consultation document). The full sentence on tiering reads: 'Further work is required to determine where specific procedures will sit in the proposed tiering system and to determine which practitioners should be permitted to carry out certain procedures.' SCOPE LIMIT: this response confers no tier on any procedure. Anyone stating that a treatment 'is green tier' is quoting the 2023 proposal, not the 2025 outcome.
5. Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 (2026 asp 13), schedule 1; and the Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 (Commencement No. 1 and Saving Provision) Regulations 2026 (S.S.I. 2026/206).Tier 1Supports: Bill passed by the Scottish Parliament 17 March 2026; Royal Assent 12 May 2026. Schedule 1 specifies 14 paragraphs of non-surgical procedures, including verbatim: 'Ablative laser treatment — A procedure in which a laser is used to remove one or more layers of skin'; 'Chemical peel — A procedure (a) in which a chemical is used to remove skins cells in the area of treatment, and (b) which penetrates deeper than the epidermis'; 'Microneedling — A procedure in which one or more microneedles are used to puncture skin multiple times on a single occasion (a) to any depth if one or more microneedles are used to deliver radio frequency electromagnetic radiation, or (b) to a depth of 1.5 millimetres or more in any other case', expressly excluding acupuncture, cosmetic body piercing, electrolysis, tattooing and injection. Also listed: dermal microcoring, injectable procedure, intravenous procedure, subcision, thread lift. COMMENCEMENT: S.S.I. 2026/206 (made 16 June 2026, in force 22 July 2026) commenced sections 1, 2(3), 4(3), 5, 14, 15, 17, 19, 20, 23 and schedules 1 and 2 only. The substantive offences — section 2(1) (providing a specified procedure to a person under 18) and section 3 (providing outwith permitted premises) — are NOT yet in force. Sections 16, 21, 22, 24 and 25 came into force the day after Royal Assent.
6. Public Health (Wales) Act 2017 (anaw 2), Part 4, section 57 ('Meaning of special procedure').Tier 1Supports: Section 57 verbatim: 'Each of the following is a special procedure for the purposes of this Part— (a) acupuncture; (b) body piercing; (c) electrolysis; (d) tattooing.' In force from 29 November 2024 by S.I. 2024/1248, art. 2(b). SCOPE LIMIT: the Welsh mandatory licensing scheme covers only these four procedures. Chemical peels, microneedling, laser, IPL and injectables are not special procedures in Wales and are not licensed under Part 4. Section 57 itself lists four bare terms; the expanded definitions sometimes quoted in training (that acupuncture includes dry needling and tattooing includes semi-permanent make-up) were not verified against the statutory text for this entry.
7. European Commission. A Guideline on Summary of Product Characteristics (SmPC), Revision 2, September 2009. Notice to Applicants, Volume 2C (29 pages).Tier 1Supports: The nearest thing to a formal regulatory definition of a contraindication that UK practice actually runs on. Section 4.3 verbatim: 'Situations where the medicinal product must not be given for safety reasons, i.e. contraindications, are the subject of this section. Such circumstances could include a particular clinical diagnosis, concomitant diseases, demographic factors (e.g. gender, age) or predispositions... The situations should be unambiguously, comprehensively and clearly outlined.' Critically, verbatim: 'Lack of data alone should not lead to a contraindication.' And: 'In general, patient populations not studied in the clinical trial programme should be mentioned in section 4.4 and not in this section unless a safety issue can be predicted.' Section 4.4 is separately headed 'Special warnings and precautions for use' — the structural home of what practitioners loosely call a 'relative contraindication'. SCOPE LIMIT: this is a European Commission guideline for the EU marketing-authorisation system. GB SmPCs use the same section numbering, but formal MHRA adoption of this particular document was not verified for this entry; do not cite it as a UK regulatory instrument. It governs licensed medicinal products, not cosmetic products, medical devices or procedures. It is cited here for its definitional discipline, not because it binds aesthetic practice.
8. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products, Article 19 (Labelling), as assimilated law applying in Great Britain.Tier 1Supports: Article 19(1)(d) verbatim requires that the container and packaging bear 'particular precautions to be observed in use, and at least those listed in Annexes III to VI and any special precautionary information on cosmetic products for professional use'. This is the legal instrument that puts precautionary wording on a professional peel or home-care product in GB: the responsible person must state precautions, and must include the specific precautions attached to restricted substances in Annexes III to VI. SCOPE LIMIT: the Regulation mandates precautions for the PRODUCT. It says nothing about which patients a practitioner should decline, does not use the word contraindication, and creates no procedure-level standard.
9. The Medical Devices Regulations 2002 (S.I. 2002/618), regulation 2 (interpretation), as amended and applying in Great Britain; MHRA is the competent authority.Tier 1Supports: Definition verbatim: '"intended purpose" means— ... (b) in relation to any other medical device, the use to which the device is intended according to the data supplied by the manufacturer on the labelling, the instructions for use and/or the promotional materials'. This is why the manufacturer's instructions for use are not merely advice: for a UKCA/CE-marked device such as a microneedling pen, laser, IPL or RF platform, the IFU is the document that defines in law what the device is for. Treating outside it is off-label use of a device, with the risk and the liability moving from the manufacturer to the practitioner. SCOPE LIMIT: this defines intended purpose; it does not itself make departure from an IFU a criminal offence for the end user, and the UK MDR 2002 predates and differs from the EU MDR 2017/745 that no longer applies in GB.
10. Waldman A, Bolotin D, Arndt KA, Dover JS, Geronemus RG, Chapas A, Iyengar S, Kilmer SL, Krakowski AC, Lawrence N, Prather HB, Rohrer TE, Schlosser BJ, Kim JYS, Shumaker PR, Spring LK, Alam M. ASDS Guidelines Task Force: Consensus Recommendations Regarding the Safety of Lasers, Dermabrasion, Chemical Peels, Energy Devices, and Skin Surgery During and After Isotretinoin Use. Dermatologic Surgery 2017;43(10):1249-1262. PMID 28498204.Tier 4Supports: The origin story of the six-month rule, stated in the paper's own background: 'Currently, the isotretinoin (13-cis-retinoic acid) package insert contains language advising the discontinuation of isotretinoin for 6 months before performing cosmetic procedures, including waxing, dermabrasion, chemical peels, laser procedures, or incisional and excisional cold-steel surgery. It is common practice to follow this standard because of concerns regarding reports of sporadic adverse events and increased risk of scarring.' Method: American Society for Dermatologic Surgery task force of 17 content experts; literature extraction, clinical question review, consensus Delphi process, peer-review validation. Conclusion verbatim: 'the task force concluded that there is insufficient evidence to justify delaying treatment with superficial chemical peels and nonablative lasers, including hair removal lasers and lights, vascular lasers, and nonablative fractional devices for patients currently or recently exposed to isotretinoin. Superficial and focal dermabrasion may also be safe when performed by a well-trained clinician.' SCOPE LIMITS: this is expert opinion by Delphi, not a trial — tier 4, not a guideline. It does NOT clear medium or deep peels, ablative lasers or full-field resurfacing. It is a US society document with no UK legal standing. Individual author conflict-of-interest disclosures could not be verified: Dermatologic Surgery full text is paywalled and the article has no PMC record.Funding / interest: Convened and authorised by the American Society for Dermatologic Surgery, a US specialty society whose meetings and activities are supported by device and pharmaceutical manufacturers. Several named authors direct commercial laser and cosmetic-surgery centres. DISCLOSURE GAP CONFIRMED ON RE-CHECK: Dermatologic Surgery full text is paywalled, there is no PMC deposit, and neither the PubMed record nor the Europe PMC core record carries a conflict-of-interest or funding statement. Individual author interests therefore remain unverified for all 18 authors.
11. Xu Y, Wang H, Guo L, Hamblin MR, Wen X. Combinations of Energy-based Devices plus isotretinoin for management of acne and acne scars: A systematic review. Journal of Cosmetic Dermatology 2024;23(10):3090-3101. PMID 38845186.Tier 1Supports: PRISMA systematic review; PubMed, Embase, Web of Science, Cochrane Library and CENTRAL searched to April 2023; two independent reviewers. Sixteen studies included: 6 randomised controlled trials, 2 case series, 7 cohort studies, 1 case report. Devices covered: intense pulsed light, fractional ablative CO2, pulsed dye laser, non-ablative fractional laser and fractional microneedle radiofrequency. Conclusion verbatim: 'The current evidence does not justify delaying the use of EBDs for patients who have recently undergone or are currently receiving ISO treatment. Evidence-based treatments such as PDL, NAFL, and FMRF etc. are suggested relatively safe and effective in treating acne and acne scarring.' Author list, journal, volume, pages, PMID and DOI (10.1111/jocd.16407) all verified against PubMed and Europe PMC. SCOPE LIMITS: energy-based devices only — chemical peels were not the subject of this review. Sixteen heterogeneous studies with no pooled effect estimate, dominated by small samples; a review of this size cannot exclude uncommon harms such as keloid or hypertrophic scarring, which is the specific risk the six-month rule was meant to address.Funding / interest: NOT RETRIEVABLE. Journal of Cosmetic Dermatology full text is behind a Wiley paywall (HTTP 402) and neither the PubMed record nor the Europe PMC core record carries a funding or conflict-of-interest statement. Noted for transparency: four authors are at West China Hospital, Sichuan University, and the fifth, Michael R Hamblin, is at the Laser Research Centre, University of Johannesburg — an institutional interest in the class of devices under review. No commercial funding was found; none can be excluded either.
12. He SX, Wang Y, Wang J, Tang L, Yang L, Ye FL. Isotretinoin Combined Laser/Light-Based Treatments Versus Isotretinoin Alone for the Treatment of Acne Vulgaris: A Meta-Analysis. Journal of Cosmetic Dermatology 2025;24(1):e16639. PMID 39509291, PMCID PMC11743250.Tier 1Supports: PRISMA meta-analysis, databases searched to December 2023; 6 studies, 285 patients (studies published 2018-2023, mean ages 18-30). Clinical improvement favoured combination therapy, OR 2.69 (95% CI 1.27-5.69, p=0.01). Long-term adverse events showed no statistically significant difference: dryness OR 2.70 (95% CI 0.35-20.59, p=0.34); cheilitis OR 0.75 (95% CI 0.19-2.89, p=0.67); hyperpigmentation OR 15.43 (95% CI 0-81,825.87, p=0.53). Treatment-related discomfort was significantly higher with combination: pain OR 119.52 (95% CI 9.69-1475.00), oedema OR 1147.52 (95% CI 68.91-19,109.38), erythema OR 1628.09 (95% CI 223.77-11,845.33). SCOPE LIMITS AND HONEST READING: the confidence intervals on the adverse-event outcomes are so wide that 'no significant difference' carries almost no information — a hyperpigmentation interval running from 0 to 81,826 means the data are compatible with substantial harm. This is an absence of evidence, not evidence of absence, and it should not be quoted as proof that combining is safe. Scarring, the outcome the six-month rule exists for, was not among the POOLED outcomes — but the paper does report it narratively, and the finding is positive and must not be omitted: verbatim, 'none of the literature studies included in our analysis reported any instances of scarring', and the authors write that combining isotretinoin with non-ablative fractional laser 'not only avoids worsening scarring and hyperpigmentation but also exhibits a noteworthy therapeutic impact on acne atrophic scarring'. Efficacy also favoured combination: clinical improvement OR 2.69 (95% CI 1.27-5.69) and total lesion reduction MD -4.48 (95% CI -7.32 to -1.64). Zero events across six small studies is weak evidence of safety, not no evidence at all.Funding / interest: 'The authors received no specific funding for this work.' Conflicts of interest: 'The authors declare no conflicts of interest.'
13. Joint Council for Cosmetic Practitioners and Cosmetic Practice Standards Authority. JCCP and CPSA Code of Practice and Guidance for Practitioners Who Provide Cosmetic Interventions, Third Edition. March 2023. 33 pages.Tier 4Supports: Self-description verbatim: the JCCP and CPSA 'are not "statutory regulatory" bodies. As such, these guidelines should be seen as "best practice" for cosmetic practitioners as mandated by the JCCP and CPSA and not as being legally enforceable by statute. The JCCP is formally accredited by the Professional Standards Authority (PSA).' The Code cites Montgomery directly at paragraph 44 (footnote: 'See Montgomery v Lanarkshire Health Board (Scotland) [2015] UKSC 11'), requiring practitioners to 'talk to the person about any adverse outcomes and risks that may result from the proposed intervention, paying particular attention to those the patient is most concerned about.' Paragraph 38 requires that 'Your discussions must be recorded contemporaneously in your clinical notes'. Paragraph 48 requires that where a client refuses GP involvement, 'you must record this in their notes and consider how this affects the balance of risk and benefit and whether you should go ahead with the intervention'. Paragraph 60 is a 'should', not a 'must': 'You should organise your records in a way that allows identification of clients/patients who have been treated with a particular device or medicine in the event of product safety concerns or regulatory enquiries.' (Paragraphs 38 and 48, by contrast, are 'must' obligations.) VERIFIED NEGATIVE: a full-text search of the 33-page document returns ZERO occurrences of 'contraindication', 'contra-indication', 'absolute' or 'precaution'. The document that most UK aesthetic practitioners are told is their professional standard does not use the word at all. This negative was independently re-run on the same 33-page PDF on 1 August 2026 and reproduced exactly: 0 / 0 / 0 / 0. The Code also does not enumerate the five JCCP/CPSA modalities — that list is published elsewhere (source 17), not here.
14. Cosmetic Practice Standards Authority. Skin Rejuvenation Standards (chemical peels and micro-needling). CPSA; document dated February 2018, 18 pages.Tier 4Supports: The benchmark standard for the skin rejuvenation modality (peels and microneedling) under the JCCP/CPSA framework. It uses the heading 'patient-related cautions', not contraindications, and states verbatim: 'The use of peels is not recommended during pregnancy'; 'Caution is advised when using peels during breast feeding, with avoidance of the breast/nipple area'; 'Caution is advised for patients with anticipated wound healing problems, including: Diabetes types 1 and 2, steroids, smoking, immunosuppression/immune modulating medications'; 'Caution is advised for patients taking photosensitising medications'. For microneedling: 'The use of micro-needling is not recommended during pregnancy or breastfeeding.' On the source of protocol authority, verbatim: peels and micro needles are handled 'As per manufacturer's guidelines', and 'A policy must be in place to follow the manufacturer protocol within clinical parameters'; and for pre-treatment testing, 'A clear policy must be in place regarding manufacturer guidelines to be followed for pre peel prep or allergy testing'. On consent it states risks 'should be discussed and documented with a patient according to GMC and Department of Health guidance', citing the GMC consent guidance and the DH Reference guide to consent for examination or treatment (2nd edition). PRECISION NOTE: the word 'contraindication' does appear once in the 18-page document, but incidentally and about positioning rather than patient selection — 'Patients should be encouraged to recline on the couch (unless medical contraindication)'. It is never used as a heading or as a category of patient. The document also carries cautions the entry does not quote: micro-needling 'is not recommended within the orbital rim'; 'Caution is advised with psoriasis or skin disease'; 'Caution is advised, and skin preparation may be necessary with darker skin types (Fitzpatrick skin type 3 or higher)'; and advice to consider stopping self-medicated anticoagulants 5-7 days before needling. SCOPE LIMITS: no evidence citations are given for any of the cautions; no absolute contraindication is stated anywhere; the document is dated February 2018 and its GMC citation points to guidance superseded by the GMC's 2020 Decision making and consent; and it directs practitioners who are largely not doctors to guidance that binds only doctors. It carries no statutory force.
15. Ofqual, Register of Regulated Qualifications — Units full extract (Units.csv, 303,554 unit records). Downloaded and analysed 2 August 2026; counts independently re-run on the same file 2 August 2026. Ofqual regulates qualifications in England.Tier 3Supports: Original analysis of the regulator's official extract, performed for this entry and then independently replicated. Of 303,554 unit records: 291 mention contraindications (any spelling) in the Title or Learning Outcomes fields (63 'contraindication', 230 'contra-indication', 0 'contra indication'); exactly ONE mentions 'absolute contraindication', and it is 'Supporting perinatal physical activity, exercise, health, and wellbeing' — a perinatal exercise unit, not an aesthetics unit; ZERO mention 'relative contraindication'; ZERO mention isotretinoin or Roaccutane anywhere in the extract. Filtering to units whose TITLES contain 'chemical peel', 'skin peel', 'microneedling' or 'micro-needling' returns 25 units, 24 of which were still live as at 2 August 2026 (one CIBTAC peel unit was withdrawn in 2020; two OTHM units carry a future withdrawal date of 2035 and are therefore still current). Those 24 live units come from SIX awarding organisations — VTCT Skills (7), Qualifi (6), CIBTAC (5), OTHM (2), ProQual (2), Focus Awards (2) — at Levels 4 to 7. Of those 24, only ONE has a learning outcome mentioning contraindications at all: CIBTAC 'Provide Micro-needling Treatment' (Level 4), learning outcome 1 verbatim — 'Understand the effects and benefits of treatment, the indications for treatment and contraindications'. It does not say which. SCOPE LIMITS: the register is Ofqual's and covers qualifications regulated in England (Wales and Scotland have separate regulators); the Learning Outcomes field in the extract is a summary and a fuller qualification specification may name contraindications in assessment criteria not captured here; this is a counting exercise on titles and learning outcomes, not a reading of every specification. CORRECTION ON VERIFICATION: an earlier draft of this entry stated 294 units, 26 title matches, 23 current units and five awarding organisations. The correct figures are 291, 25, 24 and six.
16. Hamilton Fraser. Medical malpractice insurance — cosmetic insurance for aesthetic practitioners. Company web page, accessed 2 August 2026.Tier 4Supports: A worked example of how a UK aesthetics insurer sets practitioner scope. Verbatim: 'You can perform all the treatments listed in the treatment group you select, including all treatments prior to your selection, providing you have the relevant theoretical and practical face to face training and qualifications. Please note that in respect to all injectable training, this must be provided by a Medical Professional.' On profession-based limits, verbatim: 'Hamilton Fraser can insure non-medics to carryout specific treatments subject to training requirements, but we don't insure non-medics such as beauty therapists or dental nurses for injectable treatments. We can only provide cover for dermal filler within your medical malpractice insurance policy if you are a qualified healthcare professional.' The public 'Essential' treatment group is listed as botulinum toxin, general temporary dermal fillers and chemical peels, priced from £478.80 for nurses and doctors and from £438.80 for dentists — a price that is set by the practitioner's profession, not by the treatment. SCOPE LIMITS: this is a public marketing page, not a policy wording. The binding contractual terms, exclusions and any treatment-specific conditions sit in the policy document, which is not publicly available. It is cited to show that scope is set by profession, training route and product group — not by clinical evidence — and it demonstrates that an insurer can be more restrictive than both the law and the professional standards.Funding / interest: Hamilton Fraser is a commercial insurance broker selling cosmetic and medical malpractice policies to the practitioners it is describing. Its published treatment groupings are underwriting categories with a direct commercial purpose, not clinical risk assessments.
17. Joint Council for Cosmetic Practitioners. Press Release 31 — JCCP publish guidelines on 'Adjunctive Therapies and Orphan Treatments'. JCCP; 4 pages, undated on the document itself.Tier 4Supports: The document that actually names the five benchmarked modalities — the JCCP/CPSA Code of Practice (source 13) does not. Verbatim: 'There are five core modalities in non-surgical aesthetics which the JCCP and the CPSA (The Cosmetic Practice Standards Authority) have mapped and published standards against and our registrants are expected to evidence their competence in line with these frameworks for each modality they perform.' The footnote enumerates them verbatim: 'Hair Restoration Surgery; Injectable Toxins; Dermal Fillers; Lasers and Light and Skin Rejuvenation (Micro-Needling and Chemical peels).' On everything else, verbatim: adjunctive and orphan treatments 'are not currently recognised by the JCCP or CPSA as "registered modalities" and as such the Council has not set or adopted benchmark standards of proficiency for these treatments and is unable endorse evidence of practitioner competence to perform them safely or effectively.' SCOPE LIMITS: this is a self-published press release by a voluntary register, not a standard, not a guideline and not law. The document carries no date on its face and the year given here is an estimate; it is cited only for the fact of which five modalities the JCCP/CPSA have benchmarked.Funding / interest: Self-published by the JCCP, a PSA-accredited voluntary register funded by practitioner registration fees. It has a direct organisational interest in the boundary between 'registered modality' and 'orphan treatment', because that boundary defines what its register covers.